Seems like with omicron, working inactivated vaccines appear comparably effective at preventing severe cases considering mRNA does not substantively prevent breakthrough infections. I mean they are on paper, but in practice it means buying a few extra days before spread goes out of control. It's down to costs, manufacturability and logistics. Then arguably inactivated vaccines come out ahead as most countries can produce them and they have no cold chain requirements. A country that can afford and has the capability to go all mRNA will be better off for it. But it terms of global vax effort they're now relatively less effective than inactivated solutions.